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Sir,
In a recent manuscript, van Gorp et al (2011) compared the
diagnostic performance of serum tumour markers CA125 and HE4
and the ROMA clinical risk stratification tool in a prospective
collection of serum samples from patients with ovarian mass. They
reported statistically insignificant differences between these three
diagnostic tests. However, the non-significance of the results may
be due to lack of power. A weakness of the study is that the authors
have not explained how they calculated the sample size and what
the power of the study was. Van Gorp et al started enrolling
patients in August 2005 and ended in March 2009. The first
publication on the diagnostic performance of ROMA became
available in 2008 (Moore et al, 2008), and there were no published
papers on the diagnostic performance of either ROMA or HE4 in
2005. Therefore, it is unlikely that the authors had prior knowledge
on the performance of these tests that could have been used for
sample size and power calculations. Since enrolment and design of
this prospective study preceded the publications of the tests that it
intended to validate, this raises the question if the study originally
was started as a generic pelvic mass diagnostic study and was
re-interpreted as a validation trial after the first ROMA and HE4
publications came out. It is unclear from the publication if all
enrolled patients were tested for HE4, CA125 and ROMA or only
subsamples. Publication of the selection criteria, if any, is critically
important, as it could lead to bias in the results. We think that the
incomplete description of the study objectives and study popula-
tion substantially weakens the conclusions. The non-significant
differences in test performance were interpreted by van Gorp et al
as equivalence in test performance. The authors stated that ‘HE4
and ROMA did not increase the detection of malignant disease
compared to CA125 alone and neither HE4 nor ROMA increased
the detection of malignant disease’. However, the AUC (95% CI)
values for ROMA, CA125 and HE4 were 0.898 (0.863–0.926), 0.877
(0.840–0.908) and 0.857 (0.819–0.891), respectively, which shows
a trend for better performance for ROMA. Approximate 95%
confidence intervals (CIs) can be calculated from the data
presented in the paper: AUC(ROMA)–AUC(CA125)¼ 0.021
(0.009 to 0.051), AUC(ROMA)–AUC(HE4)¼ 0.041 (0.017 to
0.065), AUC(CA125)–AUC(HE4)¼ 0.020 (0.018 to 0.058). There-
fore, about 5.1–6.5% AUC gain when using ROMA in place of
CA125 or HE4 cannot be excluded with statistical certainty. Van
Gorp et al concluded that measurement of HE4 serum levels does
not contribute to the diagnosis of ovarian cancer. This conclusion
could have relied on comparisons between AUC(CA125) and
AUC(CA125 and HE4 combined) or AUC(CA125 and menopausal
status combined) vs AUC(ROMA); however, such comparisons
were not described in the paper. The AUC(ROMA)–AUC(CA125)
comparison may be considered here, and according to the
approximate 95% CI the gain may be as large as 5.1%, less the
gain attributable to considering menopausal status. Van Gorp et al
stated that even for the pre-menopausal patients, HE4 and ROMA
did not perform better than CA125. Indeed, in this study among
pre-menopausal patients, CA125 had a higher AUC than either
HE4 or ROMA. These were, however, not significant, and the wide
CIs did not even exclude the case that ROMA was 6.1% higher than
CA125 in terms of AUC. Based on these considerations, a more
appropriate conclusion would be the following: In this study
ROMA had a higher AUC value discriminating between malignant
and benign tumours than CA125 alone by 2.1%; this difference
was, however, not significant. A rough approximation of the 95%
confidence interval of the AUC gain (0.009 to 0.051) does not
exclude a large 5.1% AUC gain when using ROMA in place of
CA125 alone, but an AUC loss of 0.9% is also compatible with the
data. In the pre-menopausal subgroup ROMA performed worse
than CA125 alone, AUC difference 0.010 (rough CI: 0.081 to
0.061); the wide CI allows for both a substantial AUC gain and a
substantial AUC loss.
A further important consideration is that the Van Gorp’s study
had a high cancer incidence (41.4%) rate in comparison with
Moore’s study (24.3%) (Moore et al, 2009) and a much higher
proportion of postmenopausal women were included (B74% in
Van Gorp vs 53% in the Moore study). There were also differences
in the distribution of histological types of tumours. Important
differences that could account for the weaker performance of HE4
in the Van Gorp’s study include higher proportion of mucinous
tumours, LMPs and metastatic tumours of extra-ovarian origin,
and lower number of serous tumours. There was also a small
difference in Stage I/II vs Stage III/IV distribution, with more
early-stage tumours in Van Gorp’s study. Moore’s study had a
higher proportion of serous EOC (64.3 vs 52.2%) and more of the
endometrioid type (12.4% vs only 4.3% in Van Gorp’s study).
These histological types tend to overexpress HE4 and contribute to
favourable HE4 performance. Van Gorp’s study had more
mucinous tumours (13 vs 4.7% in Moore’s study). This tumour
type tends not to express HE4 and contributes to the lower
performance of HE4. Van Gorp’s study had a higher proportion of
LMPs (23.7% vs 12.3% in Moore’s study) and HE4 tends to lack the
sensitivity to detect non-invasive LMP.*Correspondence: Dr G Borgulya; E-mail: G.Borgulya@sgul.ac.uk
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Van Gorp et al stated that combining HE4 and CA125 in
ROMA improved HE4 but not CA125 performance. As CA125 is
the current standard for comparison, this means neither HE4 nor
the ROMA improved the diagnosis of ovarian cancer. This
statement is also debatable, as it is not shown what percentage
of patients had increased levels of CA125 in this study. If the
majority of patients had increased CA125, in the first place no
marker alone or marker combination could improve on it. The
interpretation of the HE4 thresholds is also arguable: the optimal
threshold depends on the characteristics of the population and the
consequences of the true and false test outcomes; but in any case
HE4 is not intended to be used for screening in a group
comparable to the healthy controls, rather among patients with
adnexal mass.
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